NeOnc CEO, CMO buy $629K in company shares
NeOnc Technologies highlights significant insider open‑market share purchases following positive NEO100 Phase 2a data and a recent $15 million registered direct offering.
Rhea-AI Filing Summary
NeOnc Technologies Holdings, Inc. (NTHI) reported that Executive Chairman, President and CEO Amir F. Heshmatpour bought an additional 35,000 shares of common stock in the open market on September 15, 2026, for approximately $115,400 at a weighted average price of about $3.30 per share.
Since the company announced positive topline Phase 2a results for intranasal NEO100 on August 12, 2026, Mr. Heshmatpour has accumulated 111,000 shares for roughly $418,700, while Founder and Chief Medical Officer Thomas C. Chen has purchased 49,016 shares for about $210,000, for combined open‑market purchases of 160,016 shares totaling approximately $629,000.
The Phase 2a NEO100-01 study met its primary endpoint, with six‑month progression‑free survival of 48.9% versus a 20% benchmark (p = 0.0047) and median overall survival of 26.09 months, and follows a previously announced $15 million registered direct offering, while NeOnc’s second program, NEO212, has completed Phase 1 dose escalation and set a recommended Phase 2 dose.
Positive
- None.
Negative
- None.
Filing Explained
The filing qualifies the positive NEO100 result: it came from a 24-patient, single-arm, open-label study that did not reach planned enrollment, lacked a randomized control arm, and may not predict larger studies or determine the FDA’s view.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Latest CEO purchase: 35,000 shares for approximately $115,400
Total CEO purchases since August 12, 2026: 111,000 shares for approximately $418,700
Total CMO purchases: 49,016 shares for approximately $210,000
+5 more
8 metrics
Latest CEO purchase
35,000 shares for approximately $115,400
Open‑market purchase on September 15, 2026 at about $3.30 per share
Total CEO purchases since August 12, 2026
111,000 shares for approximately $418,700
Following announcement of positive NEO100 Phase 2a results
Total CMO purchases
49,016 shares for approximately $210,000
Open‑market purchases by Thomas C. Chen
Combined executive purchases
160,016 shares for approximately $629,000
Open‑market insider purchases reflected in Form 4 filings
Registered direct offering amount
$15 million
Registered direct offering announced on September 9, 2026
Six‑month progression‑free survival
48.9% vs 20% benchmark
Primary endpoint in NEO100-01 Phase 2a study (p = 0.0047)
Median overall survival
26.09 months
Outcome from NEO100-01 Phase 2a study
NEO100 Phase 2a enrollment
24 patients
Single‑arm, open‑label study that did not reach planned 28 patients
Key Terms
registered direct offering, Phase 2a, progression-free survival, median overall survival, +2 more
6 terms
registered direct offering financial
"The purchase follows the Company’s $15 million registered direct offering announced"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Phase 2a medical
"positive topline Phase 2a results for intranasal NEO100"
Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.
progression-free survival medical
"six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
median overall survival medical
"and median overall survival of 26.09 months"
Median overall survival is the middle point of how long patients live after starting treatment, meaning half live longer and half live shorter. It helps doctors understand how effective a treatment is and gives patients an idea of what to expect about their future.
Fast-Track regulatory
"are in Phase II human clinical trials and are advancing under FDA Fast-Track"
A fast-track designation is a regulatory status granted to a potential medical product that aims to speed up development and review because it could address an unmet medical need. For investors, it means the company may reach approval milestones and market access sooner than usual — like getting a VIP pass through airport lines — which can reduce time, cost and risk in bringing a product to patients and revenue.
Investigational New Drug (IND) regulatory
"advancing under FDA Fast-Track and Investigational New Drug (IND) status"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider stock purchases did NTHI report on September 16, 2026?
NeOnc reported that CEO Amir F. Heshmatpour bought 35,000 shares on September 15, 2026, for approximately $115,400 at a weighted average price of about $3.30 per share, in open‑market transactions funded with personal funds.
What key efficacy results did NeOnc (NTHI) report for the NEO100-01 Phase 2a study?
The NEO100-01 Phase 2a study met its primary endpoint with six‑month progression‑free survival of 48.9% versus a 20% benchmark (p = 0.0047), and showed median overall survival of 26.09 months, based on a single‑arm, open‑label study of 24 patients.
What recent financing did NeOnc Technologies (NTHI) reference in this disclosure?
NeOnc stated that the insider purchases follow a $15 million registered direct offering announced on September 9, 2026, adding this financing context to the reported open‑market common stock purchases by senior leadership.
What is the status of NeOnc’s NEO212 program mentioned in the 8-K?
NeOnc reported that NEO212 has completed Phase 1 dose escalation and has established a recommended Phase 2 dose, positioning this second clinical program to advance further in development.
How much has the NeOnc (NTHI) CEO invested personally over the past year?
Amir F. Heshmatpour stated that, with his most recent open‑market purchases, he has invested more than $1.5 million of his personal funds in NeOnc shares over the past year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
